farnesol has been researched along with Cell Transformation, Neoplastic in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (90.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brenner, DA; Cox, AD; Der, CJ; Garcia, AM; Kowalczyk, JJ; Lewis, MD; Westwick, JK | 1 |
| Buss, JE; Cox, AD; Der, CJ; Solski, PA; Willumsen, BM | 1 |
| Hamilton, AD; McGuire, TF; Qian, Y; Sebti, SM; Vogt, A | 1 |
| Fujii, T; Itoh, A; Kohgo, Y; Nishino, N; Obara, T; Shudo, R; Tanno, S; Ura, H | 1 |
| Bifulco, M; Di Marzo, V; Laezza, C | 1 |
| Ben-Baruch, G; Egozi, Y; Gana-Weisz, M; Kloog, Y; Weisz, B | 1 |
| Eskens, FA; Stoter, G; Verweij, J | 1 |
| Buss, JE; Cox, AD; Der, CJ; Hisaka, MM | 1 |
| Buss, JE; Cox, AD; Der, CJ; Graham, SM; Hisaka, MM; Kato, K | 1 |
| Bourne, JR; Buss, JE; Cochrane, CG; Der, CJ; Jackson, JH; Solski, PA | 1 |
1 review(s) available for farnesol and Cell Transformation, Neoplastic
| Article | Year |
|---|---|
Farnesyl transferase inhibitors: current developments and future perspectives.
Topics: Alkyl and Aryl Transferases; Cell Transformation, Neoplastic; Clinical Trials as Topic; Enzyme Inhibitors; Farnesol; Genes, ras; Humans; Research Design | 2000 |
9 other study(ies) available for farnesol and Cell Transformation, Neoplastic
| Article | Year |
|---|---|
The CAAX peptidomimetic compound B581 specifically blocks farnesylated, but not geranylgeranylated or myristylated, oncogenic ras signaling and transformation.
Topics: 3T3 Cells; Animals; Cell Transformation, Neoplastic; Diterpenes; DNA-Binding Proteins; ets-Domain Protein Elk-1; Farnesol; Mice; Myristic Acid; Myristic Acids; Oligopeptides; Oncogene Protein p21(ras); Protein Prenylation; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-jun; Retroviridae Proteins, Oncogenic; Signal Transduction; Transcription Factors; Transcription, Genetic | 1994 |
Novel determinants of H-Ras plasma membrane localization and transformation.
Topics: Animals; Binding Sites; Cell Membrane; Cell Transformation, Neoplastic; Cysteine; Farnesol; Genes, ras; Mice; Mutation; Myristic Acids; Palmitates; ras Proteins; Sensitivity and Specificity | 1996 |
Protein geranylgeranylation, not farnesylation, is required for the G1 to S phase transition in mouse fibroblasts.
Topics: Actins; Alkyl and Aryl Transferases; Animals; Benzamides; Cell Cycle; Cell Division; Cell Transformation, Neoplastic; Cells, Cultured; Cytoskeleton; Diterpenes; DNA; Enzyme Inhibitors; Farnesol; Fibroblasts; G1 Phase; Genes, ras; GTP-Binding Proteins; Lovastatin; Methionine; Mevalonic Acid; Mice; Protein Prenylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-raf; rap GTP-Binding Proteins; ras Proteins; Resting Phase, Cell Cycle; S Phase; Transferases | 1996 |
Selective cytotoxicity of farnesylamine to pancreatic carcinoma cells and Ki-ras-transformed fibroblasts.
Topics: 3T3 Cells; Alkyl and Aryl Transferases; Animals; Apoptosis; Cell Transformation, Neoplastic; DNA Fragmentation; Enzyme Inhibitors; Farnesol; Genes, ras; Mice; Pancreatic Neoplasms; Protein Prenylation; Proto-Oncogene Proteins p21(ras); Signal Transduction | 1998 |
v-K-ras leads to preferential farnesylation of p21(ras) in FRTL-5 cells: multiple interference with the isoprenoid pathway.
Topics: Alkyl and Aryl Transferases; Animals; Cell Line, Transformed; Cell Transformation, Neoplastic; Farnesol; Farnesyltranstransferase; Genes, ras; Oncogene Protein p21(ras); Phosphotransferases (Alcohol Group Acceptor); Signal Transduction; Thyroid Gland | 1998 |
Growth inhibition of ras-dependent tumors in nude mice by a potent ras-dislodging antagonist.
Topics: 3T3 Cells; Actins; Animals; Antineoplastic Agents; Cell Division; Cell Transformation, Neoplastic; Cytoskeleton; Farnesol; Genes, erbB-2; Genes, ras; Male; Mice; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms, Experimental; Neuroblastoma; Oncogene Proteins v-raf; Protein Prenylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins p21(ras); Rats; Receptor, ErbB-2; Retroviridae Proteins, Oncogenic; Salicylates; Substrate Specificity; Tumor Cells, Cultured | 1999 |
Specific isoprenoid modification is required for function of normal, but not oncogenic, Ras protein.
Topics: 3T3 Cells; Amino Acid Sequence; Animals; Cell Division; Cell Membrane; Cell Transformation, Neoplastic; Cysteine; Diterpenes; Farnesol; GTP-Binding Proteins; Mice; Molecular Sequence Data; Mutagenesis, Site-Directed; Protein Processing, Post-Translational; Proto-Oncogene Proteins p21(ras); Proto-Oncogene Proteins pp60(c-src); rap GTP-Binding Proteins; Structure-Activity Relationship | 1992 |
Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity.
Topics: 3T3 Cells; Amino Acid Sequence; Animals; Cell Compartmentation; Cell Membrane; Cell Transformation, Neoplastic; Endopeptidases; Farnesol; Methylation; Mice; Molecular Sequence Data; Mutagenesis, Site-Directed; Protein Processing, Post-Translational; Proto-Oncogene Proteins p21(ras) | 1992 |
Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation.
Topics: Animals; Anticholesteremic Agents; Cell Line; Cell Transformation, Neoplastic; Cells, Cultured; Exons; Farnesol; Genetic Vectors; Humans; Lovastatin; Mevalonic Acid; Mice; Mutation; Oligonucleotide Probes; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Transfection | 1990 |